$OTLC Income Statement | Understand Stock

$OTLC

$0.03 -$0.00 (1.91%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Service
Total Revenue
Operating expenses:
Research and development
General and administrative
Goodwill impairment loss
Total operating expenses
Income/(Loss) from operations
Other income (expense):
PPP loan forgiveness
Change in fair value of investment in GMP Bio
Interest expense, net
Reimbursement for expenses - related party
Change in fair value of derivative on debt
Debt extinguishment
Gain on derecognition of non-financial asset
Miscellaneous income
Total other income (expense)
Net income (loss) before income taxes
Provision for income taxes
Net income loss

Net loss attributable to non-controlling interests
Net income (loss) attributable to Oncotelic Therapeutics, Inc.
Basic net income (loss) per share attributable to common stock
Basic weighted average common stock outstanding
Basic and diluted net income (loss) per share attributable to common stock
Basic and diluted weighted average common stock outstanding

Comments